Home Cart Sign in  
Chemical Structure| 6990-06-3 Chemical Structure| 6990-06-3
Chemical Structure| 6990-06-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fusidic acid, also known as Fucidin and SQ-16603, can inhibit protein synthesis and is used to treat bacterial infections.

Synonyms: Fusidate; SQ-16603; CEM-102

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Samaneh Toufanian ; Jody Mohammed ; Erica Winterhelt ; Andrew Lofts ; Ridhdhi Dave ; Brian K. Coombes , et al.

Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) is associated with high levels of morbidity and is considered a difficult-to-treat infection, often requiring nonstandard treatment regimens and antibiotics. Since over 40% of the emerging antibiotic compounds have insufficient solubility that limits their bioavailability and thus efficacy through oral or intravenous administration, it is crucial that alternative drug delivery products be developed for wound care applications. Existing effective treatments for soft tissue MRSA infections, such as fusidic acid (FA), which is typically administered orally, could also benefit from alternative routes of administration to improve local efficacy and bioavailability while reducing the required therapeutic dose. Herein, we report an antimicrobial poly(oligoethylene glycol methacrylate) (POEGMA)-based composite hydrogel loaded with fusidic acid-encapsulating self-assembled polylactic acid-b-poly(oligo(ethylene glycol) methyl ether methacrylate) (PLA-POEGMA) nanoparticles for the treatment of MRSA-infected skin wounds. The inclusion of the self-assembled nanoparticles (380 nm diameter when loaded with fusidic acid) does not alter the favorable mechanical properties and stability of the hydrogel in the context of its use as a wound dressing, while fusidic acid (FA) can be released from the hydrogel over ∼10 h via a diffusion-controlled mechanism. The antimicrobial studies demonstrate a clear zone of inhibition in vitro and a 1−2 order of magnitude inhibition of bacterial growth in vivo in an MRSA-infected full-thickness excisional murine wound model even at very low antibiotic doses. Our approach thus can both circumvent challenges in the local delivery of hydrophobic antimicrobial compounds and directly deliver antimicrobials into the wound to effectively combat methicillin-resistant infections using a fraction of the drug dose required using other clinically relevant strategies.

Keywords: biomaterials ; wound care ; wound dressing ; antimicrobial resistance ; hydrogels ; self-assembled nanoparticles ; drug release kinetics ; copolymer

Purchased from AmBeed:

Alternative Products

Product Details of Fusidine

CAS No. :6990-06-3
Formula : C31H48O6
M.W : 516.71
SMILES Code : CC(C)=CCC/C(C(O)=O)=C1[C@@H](OC(C)=O)C[C@]2(C)[C@@]3(C)CC[C@@]4([H])[C@H](C)[C@H](O)CC[C@]4(C)[C@]3([H])[C@H](O)C[C@@]/12[H]
Synonyms :
Fusidate; SQ-16603; CEM-102
MDL No. :MFCD00865135
InChI Key :IECPWNUMDGFDKC-MZJAQBGESA-N
Pubchem ID :3000226

Safety of Fusidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P501-P270-P264-P301+P312+P330
 

Historical Records

Categories